Rethinking "More Is Better": Deescalating Cancer Care

As cancer care becomes increasingly personalized, treatment deescalation is emerging as a key strategy to balance efficacy with quality of life. In this episode of Cancer Advances, Jame Abraham, MD, Enterprise Chair of Hematology and Medical Oncology at Cleveland Clinic, discusses how clinicians are rethinking dose intensity, duration and therapeutic selection across disease settings. Learn how evolving evidence, patient preferences and emerging technologies like AI are shaping treatment decisions and redefining standards of care.